Press Releases
Apr 1, 2024

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of...

Mar 27, 2024

At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of...

Mar 18, 2024

PITTSBURGH, March 18, 2024 – As previously disclosed on February 28, 2024, Viatris Inc. entered into agreements for a global research and development collaboration with Idorsia Ltd (SIX: IDIA)....

Mar 12, 2024

PITTSBURGH, March 12, 2024 – As previously disclosed on October 1, 2023, Viatris Inc. entered into a definitive agreement with Insud Pharma, a leading Spanish multinational pharmaceutical...

Mar 11, 2024

Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the U.S. Food and Drug...

Feb 28, 2024

Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1...

Feb 28, 2024

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand...

Feb 5, 2024

Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financial markets. Chief Executive Officer...

All Press Releases

Engage with Us
More Information
  • Media Contacts
  •  
  • +1.724.514.1800
  • communications@viatris.com
  •  
  • Contact Us

  • Listen Well Podcast
  •  
  • Explore a new kind of health podcast.
  •  
  • Listen Now

  • Email Alerts
  •  
  • Sign up to receive the latest news and stories to your email.
  •  
  • Subscribe

Explore Viatris News